UnitedHealth Surprises Wall Street and Signals Turnaround

UnitedHealth delivered a second-quarter result that few on Wall Street expected. The largest health insurer in the United States reported a net income of $5.48 billion, equivalent to $6.04 per share. Analysts' consensus pointed to $4.91 per share. The difference is significant: over 23% above expectations.

However, the most closely watched number by the market was another one. The medical-loss ratio, an indicator that measures the claims experience of the operation, stood at 86.7% for the quarter. Analysts projected 88.4%. For a company that had been pressured precisely by rising healthcare costs, the improvement of 1.7 percentage points represents a significant change in trajectory.

The company, currently valued at $392 billion, revised its annual guidance. The earnings per share expectation jumped from $18.25 to a range between $19.50 and $20. The stock opened up more than 10% on the day the results were made public but gave back some of the gains throughout the trading session.

The turnaround began to take shape about a year ago when Stephen Hemsley resumed the role of CEO. Hemsley, who had previously led the company and held the position of chairman, returned to the post after his predecessor, Andrew Witty, resigned amid weak results and a sharp decline in stock prices.

The central issue was Medicare Advantage, a government health program primarily aimed at the elderly population. UnitedHealth is one of the largest operators of this program and had been losing money on it. Beneficiaries began to utilize more consultations, tests, and procedures than the company had projected in its actuarial forecasts. At the same time, the U.S. government tightened oversight on payments made to insurers and slowed the growth rate of reimbursements.

The combination of rising costs and pressured revenue created the crisis scenario that led to the leadership change. As we have followed in financial news, health companies in the U.S. have faced a difficult cycle of high claims experience in recent quarters.

Since taking over, Hemsley has implemented a broad restructuring. He replaced much of the senior management, reduced the network of doctors in Optum, the company's health services vertical, and decreased the number of beneficiaries in the main Medicare Advantage plans. After years of aggressive growth, the company opted to shrink to stabilize.

CFO Wayne DeVeydt explained to investors that the first signs of recovery appeared in the first quarter but gained consistency in the following months. According to him, the performance in the second quarter reflects a combination of three factors: redesign of health plans, increase in premiums charged, and strong work on medical costs.

One of the most relevant changes in the design of the plans was the replacement of fixed copayments with coinsurance models. In practice, beneficiaries began to bear a percentage of the cost of procedures instead of paying a fixed amount. This tends to reduce excessive use of services, one of the biggest villains of claims experience. The digital transformation in the healthcare sector also plays a central role in this equation.

Another pillar of the turnaround is the use of artificial intelligence. UnitedHealth is investing over $1.5 billion this year in AI tools with two main objectives: to cut operational costs and detect inappropriate payments.

The CFO highlighted that the company has been able to use AI to identify anomalies in medical expense billing. The interesting detail is that part of the problem comes from the other side: companies responsible for medical billing have also started using AI to optimize collections, often in questionable ways. UnitedHealth is using the same technology to combat this practice.

This movement reflects a broader trend of AI adoption in the corporate sector, where technology is moving from promise to appearing in concrete lines on the balance sheet. When a company can point to $1.5 billion in AI investments while also showing improved claims experience, the market pays attention.

The thesis emerging from the numbers is that a turnaround is happening faster than the consensus anticipated. David Wagner, manager at Aptus Capital and a shareholder in UnitedHealth, described the results as "a reminder that this could be a recovery story much quicker than most believed."

Still, it is worth considering. Medicare Advantage remains a program subject to regulatory decisions from the U.S. government. The reduction in reimbursements and increased oversight are structural risks that do not disappear with a good quarter. The company has shrunk its beneficiary base to improve profitability, which means that future revenue depends on being able to grow again, but with discipline.

For those following the U.S. healthcare sector, UnitedHealth's results serve as a thermometer. The company is the largest operator in the market, and its numbers influence perceptions about competitors like Humana, Elevance, and CVS Health. If claims experience is falling for the leader, there are chances that the same will happen across the rest of the sector, which could recalibrate expectations for the entire segment on Wall Street.

UnitedHealth's second quarter does not solve all problems. But it delivers something the market has not seen in quarters: concrete evidence that the decisions made in the restructuring are yielding results. And in corporate turnarounds, the distance between "the signs are appearing" and "the thesis has been confirmed" is often shorter than it seems.